IP Library Granted Patent US 10,167,488
Granted Patent B2
US 10,167,488 · App. 15/803,735 · Granted Jan 1, 2019

Heterologous pathway to produce terpenes

Inventors: Jay D. Keasling (Berkeley, CA); Christopher B. Eiben (Berkeley, CA)
Assignee: The Regents of the University of California
C12P5/007C12N9/0006C12N9/1025C12N9/1029C12N9/1085C12N9/1205C12N9/88C12N9/90C12N15/52C12P9/00C12Y101/01034C12Y203/01009C12Y203/0301C12Y205/01001C12Y207/01036C12Y402/03027C12Y503/03002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,167,488
App. No.
15/803,735
Granted
Jan 1, 2019
Kind
B2
Abstract

Cells comprising a heterologous metabolic pathway are configured to produce a terpene product containing non-multiples of five carbon, particularly wherein the pathway comprises heterologous Lepidoptera insect juvenile hormone biosynthetic pathway enzymes of the insect's mevalonate pathway.

Claims (7)

1. A cell genetically engineered to express a heterologous metabolic pathway comprising heterologous Bombyx mori and/or Choristoneura fumiferana mevalonate pathway enzymes, wherein the cell produces a product of the metabolic pathway that is a C16 terpene, wherein the mevalonate pathway enzymes comprise β-hydroxy β-methylglutaryl-CoA synthase (HMGS), β-hydroxy β-methylglutaryl-CoA reductase (HMGR), mevalonate kinase (MevK), mevalonate phosphate kinase (MevPK), mevalonate pyrophosphate decarboxylase (MevPPD), isopentenyl pyrophosphate isomerase (IPPI) and farnesyl pyrophosphate synthase (FPPS), wherein the metabolic pathway further comprises a terpene cyclase.

2. The cell of claim 1 , wherein the terpene cyclase is Streptomyces coelicolor epi-isozizaene synthase.

3. The cell of claim 1 , wherein the metabolic pathway further comprises propionate-CoA ligase.

4. The cell of claim 1 , wherein the metabolic pathway further comprises S. sativa valeryl-CoA synthase, E. coli FadB and/or Micrococcus luteus Aco.

5. The cell of claim 1 that is E. coli.

6. A method for producing a C16 terpene product, wherein said method comprises growing the cell of claim 1 to produce the product, and isolating or enriching the product.

7. A method of making the cell of claim 1 , wherein said method comprises genetically engineering a cell to comprise a heterologous metabolic pathway comprising a terpene cyclase and heterologous Bombyx mori and/or Choristoneura fumiferana mevalonate pathway enzymes, wherein the mevalonate pathway enzymes comprise β-hydroxy β-methylglutaryl-CoA synthase (HMGS), β-hydroxy β-methylglutaryl-CoA reductase (HMGR), mevalonate kinase (MevK), mevalonate phosphate kinase (MevPK), mevalonate pyrophosphate decarboxylase (MevPPD), isopentenyl pyrophosphate isomerase (IPPI) and farnesyl pyrophosphate synthase (FPPS), and wherein the cell produces a product of the metabolic pathway that is a C16 terpene.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 14, 2018
From: UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 046153/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2017
From: KEASLING, JAY D; EIBEN, CHRISTOPHER B
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 044034/0453 →
Continuity (2)
Provisional Application 62417299 · Nov 3, 2016
Related Publication 20180119176A1 · May 3, 2018
Cited By (4)
US 12,241,104 US 12,371,855 US 12,392,085 US 12,492,155